{
    "clinical_study": {
        "@rank": "33291", 
        "arm_group": [
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Experimental", 
                "description": "Blue light TUR-BT with no adjuvant instillations"
            }, 
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Active Comparator", 
                "description": "White light TUR-BT with no adjuvant instillations"
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Experimental", 
                "description": "White light TUR-BT with six weekly optimized mitomycin-C instillations."
            }, 
            {
                "arm_group_label": "Group D", 
                "arm_group_type": "Experimental", 
                "description": "Blue light (PDD) TUR-BT with six weekly optimized mitomycin-C instillations."
            }
        ], 
        "brief_summary": {
            "textblock": "Bladder cancer (BC), the second most common urological malignancy, is an important public\n      health issue. One of the main challenges in the treatment of bladder cancer if the\n      prevention of recurrences of non-invasive tumors, which is also associated with significant\n      costs.\n\n      The current study will investigate optimal treatment of patients with bladder cancer with\n      high risk of tumor recurrence but low risk of progression. The main interest is comparison\n      of photodynamic (PDD) bladder tumor resection (TUR-BR)to traditional TUR-BT. Also the\n      efficacy of adjuvant optimized mitomycin-C is compared to patients with no adjuvant\n      treatment."
        }, 
        "brief_title": "Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9)", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Bladder Cancer", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Primary papillary bladder cancer at high risk for further recurrence as defined as\n        follows:\n\n        Number of primary tumors \u22652, OR Size of solitary primary tumor \u2265 3 cm, OR Recurrent\n        papillary tumors\n\n          -  Histologically proven Ta bladder cancer\n\n          -  Histological grade 1-2 (WHO 1973 grading system) or papillary urothelial neoplasm of\n             low malignant potential (PUNLMP) or low grade  (WHO 2004 grading system) bladder\n             cancer\n\n          -  Written informed consent is required from every eligible patient\n\n        Exclusion Criteria:\n\n          -  Grade 3 tumors (WHO 1973 grading system), or high grade tumors (WHO 2004 grading\n             system)\n\n          -  CIS (carcinoma in situ)\n\n          -  Suspicion or evidence of papillary tumors or CIS of the upper urinary tract\n\n          -  Non-TCC (transitional cell carcinoma, i.e. urothelial carcinoma) bladder cancer\n\n          -  Suspicion or previous history of the patient not tolerating intravesical\n             instillations\n\n          -  Known allergy to MMC or hexaminolevulinate (HAL, Hexvix\u00ae)\n\n          -  Urethral stricture, stone disease, chronic urinary tract infection or any other\n             urological condition that may compromise study participation (as judged by treating\n             physician)\n\n          -  Pregnancy or lactating patient\n\n          -  Other non-cured malignancy (excepting skin basalioma or cancer in situ of the cervix\n             uteri or any other malignancy in remission \u22655 years)\n\n          -  Age < 18 years\n\n          -  Expected survival time less than one year\n\n          -  Expected poor compliance (e.g. some severe psychiatric disorders, antisocial\n             behaviour, or dementia)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01675219", 
            "org_study_id": "FinnBladder 9", 
            "secondary_id": "2012-000559-15"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group A", 
                "description": "traditional transurethral bladder tumor resection", 
                "intervention_name": "white light TUR-BT", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Group B", 
                    "Group D"
                ], 
                "description": "photodynamic transurethral bladder tumor resection", 
                "intervention_name": "blue light TUR-BT", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Group C", 
                    "Group D"
                ], 
                "description": "six weekly optimized mitomycin-C instillations", 
                "intervention_name": "optimized MMC", 
                "intervention_type": "Drug", 
                "other_name": "optimized mitomycin-C"
            }, 
            {
                "arm_group_label": [
                    "Group B", 
                    "Group A", 
                    "Group C", 
                    "Group D"
                ], 
                "description": "single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation", 
                "intervention_name": "single immediate chemotherapy instillation", 
                "intervention_type": "Drug", 
                "other_name": "single instillation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mitomycins", 
                "Mitomycin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "bladder cancer", 
            "recurrence", 
            "photodynamic diagnosis", 
            "PDD", 
            "cost analysis"
        ], 
        "lastchanged_date": "January 17, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Riikka J\u00e4rvinen, MD", 
                    "phone": "+358 50 4271015"
                }, 
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland"
                    }, 
                    "name": "HYKS Peijas Hospital"
                }, 
                "investigator": {
                    "last_name": "Riikka J\u00e4rvinen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "eero.kaasinen@hus.fi", 
                    "last_name": "Eero Kaasinen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Hyvink\u00e4\u00e4", 
                        "country": "Finland"
                    }, 
                    "name": "Hyvink\u00e4\u00e4 District Hospital"
                }, 
                "investigator": {
                    "last_name": "Eero Kaasinen, Md, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sirpa.aaltonen@kuh.fi", 
                    "last_name": "Sirpa Aaltonen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Kuopio", 
                        "country": "Finland"
                    }, 
                    "name": "Kuopio University Hospital"
                }, 
                "investigator": {
                    "last_name": "Aaltomaa Sirpa, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tapani.liukkonen@esshp.fi", 
                    "last_name": "Tapani Liukkonen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Mikkeli", 
                        "country": "Finland"
                    }, 
                    "name": "Mikkeli Central Hospital"
                }, 
                "investigator": {
                    "last_name": "Tapanki Liukkonen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "markku.vaarala@ppshp.fi", 
                    "last_name": "Markku Vaarala, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Oulu", 
                        "country": "Finland"
                    }, 
                    "name": "Oulu University Hospital"
                }, 
                "investigator": {
                    "last_name": "Markku Vaarala, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "marjo.seppanen@satshp.fi", 
                    "last_name": "Marjo Sepp\u00e4nen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Pori", 
                        "country": "Finland"
                    }, 
                    "name": "Satakunnan keskussairaala"
                }, 
                "investigator": {
                    "last_name": "Marjo Sepp\u00e4nen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sein\u00e4joki", 
                        "country": "Finland"
                    }, 
                    "name": "Sein\u00e4joki Central Hospital"
                }, 
                "investigator": {
                    "last_name": "Timo Marttila, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "juha.koskimaki@pshp.fi", 
                    "last_name": "Juha Koskim\u00e4ki, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampere", 
                        "country": "Finland"
                    }, 
                    "name": "Tampere University Hospital"
                }, 
                "investigator": {
                    "last_name": "Juha Koskim\u00e4ki, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tarmo.pekkarinen@pshp.fi", 
                    "last_name": "Tarmo Pekkarinen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampere", 
                        "country": "Finland"
                    }, 
                    "name": "Hatanp\u00e4\u00e4n sairaala"
                }, 
                "investigator": {
                    "last_name": "Tarmo Pekkarinen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Turku", 
                        "country": "Finland"
                    }, 
                    "name": "Turku University Hospital"
                }, 
                "investigator": {
                    "last_name": "Peter J. Bostr\u00f6m, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "4", 
        "official_title": "Treatment of Ta Bladder Cancer in High Risk of Recurrence - Fluorescence Cystoscopy With Optimized Adjuvant Mitomycin-C (FinnBladder 9)", 
        "other_outcome": {
            "description": "For analysis of cost-effectiveness. All bladder cancer treatment and treatment complications related costs are included.", 
            "measure": "costs", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "overall_contact": {
            "email": "peter.bostrom@tyks.fi", 
            "last_name": "Peter J Bostr\u00f6m, MD, PhD", 
            "phone": "+358 2 313035925"
        }, 
        "overall_contact_backup": {
            "email": "riikka.j\u00e4rvinen@hus.fi", 
            "last_name": "Riikka J\u00e4rvinen, MD", 
            "phone": "+358 50 427 1015"
        }, 
        "overall_official": [
            {
                "affiliation": "Turku University Hospital", 
                "last_name": "Peter J. Bostr\u00f6m, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hyvink\u00e4\u00e4 District Hospital", 
                "last_name": "Eero Kaasinen, Md, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Finland: Finnish Medicines Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "any bladder cancer recurrence at 2 years.", 
            "measure": "bladder cancer recurrence rate", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01675219"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Turku University Hospital", 
            "investigator_full_name": "Peter Bostr\u00f6m", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "bladder cancer progression to T2 or higher", 
                "measure": "Bladder cancer progression", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "progression, recurrence or side effects preventing completing the trial", 
                "measure": "Treatment failure", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "death due bladder cancer or other reasons", 
                "measure": "mortality", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Turku University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Finnbladder", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Turku University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}